Nathanael Gray, PhD

Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
Authors: Authors: Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS.
Oncogene
View full abstract on Pubmed
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Authors: Authors: Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, Gray NS.
Angew Chem Int Ed Engl
View full abstract on Pubmed
Correction to Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.
Authors: Authors: Lian W, Jang J, Potisopon S, Li PC, Rahmeh A, Wang J, Kwiatkowski NP, Gray NS, Yang PL.
ACS Infect Dis
View full abstract on Pubmed
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.
Authors: Authors: Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, Gray NS, Young RA, Geyer M, Gerber SA, George RE.
Nat Commun
View full abstract on Pubmed
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Authors: Authors: Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS.
Blood
View full abstract on Pubmed
Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.
Authors: Authors: de Wispelaere M, Lian W, Potisopon S, Li PC, Jang J, Ficarro SB, Clark MJ, Zhu X, Kaplan JB, Pitts JD, Wales TE, Wang J, Engen JR, Marto JA, Gray NS, Yang PL.
Cell Chem Biol
View full abstract on Pubmed
High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
Authors: Authors: Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, Zhang T, Wong KK, Gray NS, Young RA, Tsao H.
J Invest Dermatol
View full abstract on Pubmed
MELK is not necessary for the proliferation of basal-like breast cancer cells.
Authors: Authors: Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, Eck MJ, Dhe-Paganon S, Zhao JJ, Gray NS.
Elife
View full abstract on Pubmed
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.
Authors: Authors: Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA, Ghobrial IM.
Sci Transl Med
View full abstract on Pubmed
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Authors: Authors: Shen Y, Park CS, Suppipat K, Mistretta TA, Puppi M, Horton TM, Rabin K, Gray NS, Meijerink JPP, Lacorazza HD.
Leukemia
View full abstract on Pubmed